FY2022 Q3 Financial and R&D Update

ENHERTU Performance in Each Region (Japan, ASCA) Steady increase in product sales due to market penetration and increasing launched countries/regions Global product sales: FY2022 Q3 YTD results 139.7 Bn JPY (YOY +96.2 Bn JPY) FY2022 forecast Japan 200.4 Bn JPY (YOY +135.0 Bn JPY) Product sales: FY2022 Q3 YTD results 8.5 Bn JPY FY2022 forecast 12.4 Bn JPY ASCA Product sales: FY2022 Q3 YTD results 9.2 Bn JPY FY2022 forecast 13.6 Bn JPY Indication: HER2+ BC 2L/3L, HER2+ GC 3L Market share status HER2+ BC 3L: Maintaining No.1 new patient share ➤ HER2+ GC 3L: Maintaining No.1 new patient share Other progress ➤ Classified as a preferred regimen for HER2+ BC 2L treatment in guidelines in Japan (Jun. 2022) ➤ Approved for HER2+ BC 2L and started promotion (Nov. 2022) Indication: HER2+ BC 2L/3L, HER2 low BC (post-chemo), HER2+ GC 3L Market share status Sales growing in Brazil, Hong Kong and Taiwan Other progress ➤ Launched in Taiwan (Apr. 2022) Launched in Korea (Jan. 2023) Blue letters: updates from Q2 Daiichi-Sankyo ENHERTUⓇ trastuzumab deruxtecan 14

View entire presentation